Genematrix

Genematrix Tangible Book Value per Share

The Tangible Book Value per Share of Genematrix (109820.KQ) as of Nov 2, 2026 is 875.12 KRW. In the previous year, Tangible Book Value per Share was 960.02 KRW — a change of -8.84% (lower).

Tangible Book Value per Share

875.12KRW

YoY

-8.84%

Last updated:

Tangible Book Value per Share of Genematrix is 2025 875.12 KRW. Tangible Book Value per Share of Genematrix was 2024 960.02 KRW. It decreases by -8.84% lower compared to the previous year.

The Genematrix Tangible Book Value per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Tangible Book Value per Share
Date
Tangible Book Value per Share
Jan 1, 2018
538.70 KRW
Jan 1, 2019
759.13 KRW
Jan 1, 2020
1,668.32 KRW
Jan 1, 2021
1,615.66 KRW
Jan 1, 2022
1,206.93 KRW
Jan 1, 2023
1,156.27 KRW
Jan 1, 2024
960.02 KRW
Jan 1, 2025
875.12 KRW
The Genematrix Tangible Book Value per Share history
YEARTangible Book Value per ShareYoY
875.12KRW-8.84%
960.02KRW-16.97%
1,156.27KRW-4.20%
1,206.93KRW-25.30%
1,615.66KRW-3.16%
1,668.32KRW+119.77%
759.13KRW+40.92%
538.70KRW-2.00%
549.69KRW-11.30%
619.70KRW+47.74%
419.46KRW-13.33%
483.99KRW-40.75%
816.85KRW-10.13%
908.92KRW-9.53%
1,004.67KRW-15.52%
1,189.27KRW+5.14%
1,131.18KRW+115.10%
525.89KRW+36.48%
385.33KRW+42.95%
269.56KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genematrix Stock analysis

What does Genematrix do? Genematrix Inc develops RFMP genotyping technology for diagnosing hepatitis B virus (HBV), hepatitis C virus (HCV), and human papillomavirus (HPV) within its pharmaceutical development segment. The company manufactures and sells liver-function examination reagents through its diagnostic medicine segment, while also importing and selling medical equipment and reagents. Customers for these products include healthcare providers and medical facilities requiring viral diagnostics and liver function testing. The pharmaceutical development segment targets laboratories focused on viral infection diagnosis, while the diagnostic medicine segment serves hospitals and clinics needing reagents for liver health assessments. Genematrix Inc's revenue streams come from sales of RFMP-based diagnostic tools for HBV, HCV, and HPV testing, alongside liver-function reagent sales. The company's diagnostic medicine segment generates income through the import and sale of medical equipment and reagents, catering to healthcare institutions. Its pharmaceutical development segment focuses on viral genotyping solutions for medical laboratories, creating a dual revenue model from both diagnostic products and equipment services. The company's products are sold to healthcare institutions requiring viral diagnostics and liver function testing. Pharmaceutical development customers include medical laboratories specializing in HBV, HCV, and HPV testing, while diagnostic medicine customers are hospitals and clinics using liver-function reagents. Genematrix Inc's business model relies on direct sales of its proprietary RFMP technology and imported medical equipment to these specialized healthcare segments without third-party distribution. Genematrix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genematrix stock

Tangible Book Value per Share of Genematrix is 875.12 KRW in 2025.

Tangible Book Value per Share of Genematrix changed from 960.02 KRW to 875.12 KRW, representing a -8.84% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Tangible Book Value per Share Genematrix since 2006 – with annual values, charts, and detailed analysis.

Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Genematrix

All Key Metrics — Genematrix